Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.62 | N/A | +22.97% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.62 | N/A | +22.97% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting progress in their pipeline. However, they did not provide specific guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Ionis Pharmaceuticals reported a strong EPS performance, exceeding expectations by nearly 23%. However, the stock reacted negatively, declining by 1.88%. The lack of revenue data and forward guidance may have contributed to investor caution following the earnings announcement.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Affiliated Managers Group, Inc.